---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-012603"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2025-05-28T23:59:59+00:00"
generated_at: "2026-05-20T08:52:22.393772+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# MIRA updates on Ketamir-2 Phase 1 progress, plans Phase IIa in neuropathic pain by end of 2025

## Summary
- Participating in BIO International Convention June 16-19, 2025 for partnering and licensing discussions.
- Second dosing cohort of Ketamir-2 Phase 1 completed; company preparing to initiate third cohort.
- Phase IIa trial in neuropathic pain expected to start by end of 2025.
- Preclinical studies ongoing for PTSD and topical formulation for localized inflammatory pain.
- Finalizing regulatory filings for SKNY acquisition; SKNY-1 targets smoking cessation and obesity.

## SEC filing metadata
- accession: 0001641172-25-012603
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2025-05-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000164117225012603/0001641172-25-012603-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000164117225012603/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-012603
- JSON: https://secwatch.observer/filing/0001641172-25-012603.json
- Plain text: https://secwatch.observer/filing/0001641172-25-012603.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.